Skip to main content
OpenTrials
Completed

NCT Number: NCT00839943

Effect Of Obesity On Ozone-Induced Airway Inflammation

The purpose of this study is to compare the effect of ozone exposure on airway reactivity and inflammation in obese vs. non-obese adults.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–35 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

US EPA Human Studies Facility-UNC -CH campus

Chapel Hill, North Carolina, 27599, United States

About this study

Obesity has been shown to be associated with initial onset of asthma in children and increased airway hyperresponsiveness in adults (1,2). An important aspect of these epidemiologic data is that the impact of obesity on asthma is much stronger in females than males. For example, the incidence of asthma after the age of 11 years is five- to sevenfold higher in female children who become obese versus those who remain lean, whereas no such relationship exists for males (3). Recent mouse models of obesity suggest that this condition enhances airway responses to ozone air pollution (4). These mice eat excessively due to a defect in the gene encoding leptin, a satiety hormone produced in adipocytes. Shore et al (4) showed that these leptin-deficient obese mice had greater airway hyperreactivity to i.v. methacholine following ozone exposure compared to lean, wild-type mice. Furthermore, administration of exogenous leptin (which is actually increased in the serum of obese individuals (4)) was shown to enhance ozone-induced cytokine and protein release into BAL fluid of lean, wild type mice (4). Reduced lung volumes and altered breathing patterns in the obese may also contribute to enhanced airway reactivity in these patients (5). Stretch of airway smooth muscle during tidal breathing and especially during deep breaths, i.e. sighs, acts as a potent bronchodilator that might ameliorate ozone-induced bronchoconstriction. The increased chest load associated with obesity may also diminish tidal breathing volumes and frequency of sighs during ozone exposure.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Twenty (20) non-obese, non-overweight (body mass index, 18 kg/m2 > BMI < 25 kg/m2, waist circumference < 35 inches) subjects and 20 obese (30 kg/m2 > BMI < 38 kg/m2, waist circumference >= 35 inches) volunteer females between 18-35 yrs of age

Exclusion criteria

  • Are female and pregnant or have any reason to believe you might be pregnant.
  • Are not between 18 and 35 years old.
  • Have a history of asthma or have current hay fever.
  • Have ever smoked more than 10 cigarettes (one half pack) a month or smoked during the past 30 days.
  • Have a history of acute or chronic cardiovascular disease, chronic respiratory disease, and acute respiratory illness within 4 weeks.
  • Have contraindications for performing sustained light exercise.
  • You've been in a recent or recurring exposure to a dusty environment at work
  • If you are unwilling to refrain from strenuous physical activity for 24 hours before and after each exposure.

Treatment and study plan

ozone, 0.4 ppm

Other

2 hour ozone exposure, 0.40 ppm

Primary outcomes

  1. Methacholine reactivity (primary endpoint)

    Time frame: 2-4 hours post exposure

Secondary outcomes

  1. Breathing and lung function variables

    Time frame: immediately post exposure, 24 post exposure

  2. induced sputum markers

    Time frame: 4 hours post exposure

Sponsors and collaborators

Lead sponsor

University of North Carolina, Chapel Hill

Other

Collaborators

  • Environmental Protection Agency (EPA)
  • National Institute of Environmental Health Sciences (NIEHS)

Registry information

Acronym: OBOZ

Important dates

Study start
2006
Primary completion
2012
Study completion
2012
First posted
Feb 10, 2009
Registry last updated
Aug 27, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.